share_log

NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Apr 4 17:12
Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, has filed a post-effective amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 4, 2024. The amendment pertains to the registration of 3,000,000 ordinary shares and an equal number of warrants to purchase up to 3,000,000 ordinary shares. The warrants have an exercise price of $1.50 per ordinary share and are exercisable immediately upon issuance until June 26, 2028. This filing enables the selling shareholder, who acquired the warrants under a securities purchase agreement dated June 22, 2023, to potentially sell these securities in the public market. The company will not receive any proceeds from the sale of the ordinary shares by the selling shareholder but will incur expenses related to the offering. If the warrants are exercised for cash, NeuroSense Therapeutics may receive up to approximately $4.5 million, which it intends to use for general corporate purposes and working capital.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, has filed a post-effective amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 4, 2024. The amendment pertains to the registration of 3,000,000 ordinary shares and an equal number of warrants to purchase up to 3,000,000 ordinary shares. The warrants have an exercise price of $1.50 per ordinary share and are exercisable immediately upon issuance until June 26, 2028. This filing enables the selling shareholder, who acquired the warrants under a securities purchase agreement dated June 22, 2023, to potentially sell these securities in the public market. The company will not receive any proceeds from the sale of the ordinary shares by the selling shareholder but will incur expenses related to the offering. If the warrants are exercised for cash, NeuroSense Therapeutics may receive up to approximately $4.5 million, which it intends to use for general corporate purposes and working capital.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more